NR2E3 and Miyoshi myopathy: So, high antitumor activity of the combination of bortezomib and 4-hydroxysalicylanilide (a specific inhibitor of the RRM2 subunit of RNR) was shown against MM cell lines, including primary cells obtained from a patient with MM refractory to bortezomib [41].